Page last updated: 2024-11-03

pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid and Atherogenesis

pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid has been researched along with Atherogenesis in 1 studies

pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid: a novel antagonist that selectively blocks P2 purinoceptor receptors; a useful tool to study co-transmission in tissues when ATP and coexisting neurotransmitters act in concert
5'-phosphopyridoxal-6-azobenzene-2,4-disulfonic acid : An arenesulfonic acid that is pyridoxal 5'-phosphate carrying an additional 2,4-disulfophenylazo substituent at position 6.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Guns, PJ1
Hendrickx, J1
Van Assche, T1
Fransen, P1
Bult, H1

Other Studies

1 other study available for pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid and Atherogenesis

ArticleYear
P2Y receptors and atherosclerosis in apolipoprotein E-deficient mice.
    British journal of pharmacology, 2010, Jan-01, Volume: 159, Issue:2

    Topics: Animals; Aorta; Apolipoproteins E; Atherosclerosis; Cell Line; Interleukin-6; Macrophages; Mice; Mic

2010